Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Environmental enrichment intervention for Rett syndrome: an individually randomised stepped wedge trial

Authors: Jenny Downs, Jenny Rodger, Chen Li, Xuesong Tan, Nan Hu, Kingsley Wong, Nicholas de Klerk, Helen Leonard

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Rett syndrome is caused by a pathogenic mutation in the MECP2 gene with major consequences for motor and cognitive development. One of the effects of impaired MECP2 function is reduced production of Brain Derived Neurotrophic Factor (BDNF), a protein required for normal neuronal development. When housed in an enriched environment, MECP2 null mice improved motor abilities and increased levels of BDNF in the brain. We investigated the effects of environmental enrichment on gross motor skills and blood BDNF levels in girls with Rett syndrome.

Methods

A genetically variable group of 12 girls with a MECP2 mutation and younger than 6 years participated in a modified individually randomised stepped wedge design study. Assessments were conducted on five occasions, two during the baseline period and three during the intervention period. Gross motor function was assessed using the Rett Syndrome Gross Motor Scale (maximum score of 45) on five occasions, two during the baseline period and three during the intervention period. Blood levels of BDNF were measured at the two baseline assessments and at the end of the intervention period. The intervention comprised motor learning and exercise supplemented with social, cognitive and other sensory experiences over a six-month period.

Results

At the first assessment, the mean (SD) age of the children was 3 years (1 year 1 month) years ranging from 1 year 6 months to 5 years 2 months. Also at baseline, mean (SD) gross motor scores and blood BDNF levels were 22.7/45 (9.6) and 165.0 (28.8) ng/ml respectively. Adjusting for covariates, the enriched environment was associated with improved gross motor skills (coefficient 8.2, 95%CI 5.1, 11.2) and a 321.4 ng/ml (95%CI 272.0, 370.8) increase in blood BDNF levels after 6 months of treatment. Growth, sleep quality and mood were unaffected.

Conclusions

Behavioural interventions such as environmental enrichment can reduce the functional deficit in Rett syndrome, contributing to the evidence-base for management and further understanding of epigenetic mechanisms. Environmental enrichment will be an important adjunct in the evaluation of new drug therapies that use BDNF pathways because of implications for the strengthening of synapses and improved functioning.

Trial registration

Literature
1.
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–8.CrossRefPubMed
2.
Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment Retard Dev Disabil Res Rev. 2002;8:61–5.CrossRefPubMed
3.
Cuddapah VA, Pillai RB, Shekar KV, Lane JB, Motil KJ, Skinner SA, Tarquinio DC, Glaze DG, McGwin G, Kaufmann WE, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51:152–8.CrossRefPubMedPubMedCentral
4.
Morgan C, Novak I, Badawi N. Enriched environments and motor outcomes in cerebral palsy: systematic review and meta-analysis. Pediatrics. 2013;132:e735–46.CrossRefPubMed
5.
Lotan M, Schenker R, Wine J, Downs J. The conductive environment enhances gross motor function of girls with Rett syndrome. A pilot study. Developmental neurorehabilitation. 2012;15:19–25.CrossRefPubMed
6.
Cattaneo A, Cattane N, Begni V, Pariante CM, Riva MA. The human BDNF gene: peripheral gene expression and protein levels as biomarkers for psychiatric disorders. Transl Psychiatry. 2016;6:e958.CrossRefPubMedPubMedCentral
7.
Ben Zeev B, Bebbington A, Ho G, Leonard H, de Klerk N, Gak E, Vecksler M, Christodoulou J. The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome. Neurology. 2009;72:1242–7.CrossRefPubMed
8.
Nectoux J, Bahi-Buisson N, Guellec I, Coste J, De Roux N, Rosas H, Tardieu M, Chelly J, Bienvenu T. The p.Val66Met polymorphism in the BDNF gene protects against early seizures in Rett syndrome. Neurology. 2008;70:2145–51.CrossRefPubMed
9.
Nissenkorn A, Gak E, Vecsler M, Reznik H, Menascu S, Ben Zeev B. Epilepsy in Rett syndrome---the experience of a National Rett Center. Epilepsia. 2010;51:1252–8.CrossRefPubMed
10.
Nithianantharajah J, Hannan AJ. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006;7:697–709.CrossRefPubMed
11.
12.
Kondo M, Gray LJ, Pelka GJ, Christodoulou J, Tam PP, Hannan AJ. Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome - Mecp2 gene dosage effects and BDNF expression. Eur J Neurosci. 2008;27:3342–50.CrossRefPubMed
13.
Spruyt K, Curfs LM. Non-pharmacological management of problematic sleeping in children with developmental disabilities. Dev Med Child Neurol. 2015;57:120–36.CrossRefPubMed
14.
Boban S, Wong K, Epstein A, Anderson B, Murphy N, Downs J, Leonard H. Determinants of sleep disturbances in Rett syndrome: novel findings in relation to genotype. Am J Med Genet A. 2016;170:2292–300.CrossRefPubMed
15.
Piek JP, Kane R, Rigoli D, McLaren S, Roberts CM, Rooney R, Jensen L, Dender A, Packer T, Straker L. Does the animal fun program improve social-emotional and behavioural outcomes in children aged 4-6 years? Hum Mov Sci. 2015;43:155–63.CrossRefPubMed
16.
Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, DEK N, Leonard H. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011;70:313–9.CrossRefPubMedPubMedCentral
17.
Louise S, Fyfe S, Bebbington A, Bahi-Buisson N, Anderson A, Pineda M, Percy A, Zeev BB, XR W, Bao XH, et al. InterRett, a model for international data collection in a rare genetic disorder. Research in Autism Spectrum Disorders. 2009;3:639–59.CrossRef
18.
Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey MES, Schanen NC, Zappella M, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944–50.CrossRefPubMedPubMedCentral
19.
20.
Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, Ben-Zeev B, Yatawara N, Percy A, Kaufmann WE, Leonard H. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology. 2008;70:868–75.CrossRefPubMed
21.
22.
Reynolds S, Lane SJ, Richards L. Using animal models of enriched environments to inform research on sensory integration intervention for the rehabilitation of neurodevelopmental disorders. J Neurodev Disord. 2010;2:120–32.CrossRefPubMedPubMedCentral
23.
Shumway-Cook A, Woollacott MH. Motor control: translating research into clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
24.
Bus BA, Molendijk ML, Penninx BJ, Buitelaar JK, Kenis G, Prickaerts J, Elzinga BM, Voshaar RC. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology. 2011;36:228–39.CrossRefPubMed
25.
Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S, Knudsen GM. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull. 2007;73:143–9.CrossRefPubMed
26.
Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, Giannotti F. The sleep disturbance scale for children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5:251–61.CrossRefPubMed
27.
Malow BA, Crowe C, Henderson L, McGrew SG, Wang L, Song Y, Stone WL. A sleep habits questionnaire for children with autism spectrum disorders. J Child Neurol. 2009;24:19–24.CrossRefPubMed
28.
Bruni O, Novelli L. Sleep disorders in children. BMJ Clin Evid. 2010;2010
29.
Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The Rett syndrome behaviour questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. J Child Psychol. Psychiatry. 2002;43:1099–110.CrossRefPubMed
30.
Fehr S, Bebbington A, Ellaway C, Rowe P, Leonard H, Downs J. Altered attainment of developmental milestones influences the age of diagnosis of rett syndrome. J Child Neurol. 2011;26:980–7.CrossRefPubMed
31.
Mangatt M, Wong K, Anderson B, Epstein A, Hodgetts S, Leonard H, Downs J. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis. 2016;11:39.CrossRefPubMedPubMedCentral
32.
Kasarpalkar NJ, Kothari ST, Dave UP. Brain-derived Neurotrophic factor in children with autism Spectrum disorder. Ann Neurosci. 2014;21:129–33.PubMedPubMedCentral
33.
Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neuropharmacology. 2014;76 Pt C:737–46.CrossRefPubMed
34.
Saghazadeh A, Rezaei N. Brain-derived Neurotrophic factor levels in autism: a systematic review and meta-analysis. J Autism Dev Disord. 2017;47:1018–29.CrossRefPubMed
35.
36.
Katoh-Semba R, Wakako R, Komori T, Shigemi H, Miyazaki N, Ito H, Kumagai T, Tsuzuki M, Shigemi K, Yoshida F, Nakayama A. Age-related changes in BDNF protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci. 2007;25:367–72.CrossRefPubMed
37.
Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, DD F, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A. 2009;106:2029–34.CrossRefPubMedPubMedCentral
38.
Lonetti G, Angelucci A, Morando L, Boggio EM, Giustetto M, Pizzorusso T. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol Psychiatry. 2010;67:657–65.CrossRefPubMed
39.
Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, Nelson CA 3rd, Vogel-Farley V, DeGregorio G, Holm IA, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111:4596–601.CrossRefPubMedPubMedCentral
40.
Huang T, Larsen K T Ried-Larsen M, Moller NC, Anderson LB. The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: A review. Scandinavian Journal of Medicine and Science in Sports. 2014;24:1–10.
41.
Xu X, Garcia J, Ewalt R, Nason S, Pozzo-Miller L. The BDNF val-66-met polymorphism affects neruonal morphology and synaptic transmission in cultured hippocampal neurons from Rett syndrome mice. Front Cell Neurosci. 2017;11:1–12.
42.
Moreau D, Kirk IJ, Waldie KE. High-intensity training enhances executive function in children in a randomized, placebo-controlled trial. elife. 2017;6
43.
44.
Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553–61.CrossRefPubMed
45.
Katz DM, Bird A, Coenraads M, Gray SJ, Menon DU, Philpot BD, Tarquinio DC. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 2016;39:100–13.CrossRefPubMedPubMedCentral
Metadata
Title
Environmental enrichment intervention for Rett syndrome: an individually randomised stepped wedge trial
Authors
Jenny Downs
Jenny Rodger
Chen Li
Xuesong Tan
Nan Hu
Kingsley Wong
Nicholas de Klerk
Helen Leonard
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0752-8

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Research

Detection rate of causal variants in severe childhood epilepsy is highest in patients with seizure onset within the first four weeks of life

Research

The burden of congenital hyperinsulinism in the United Kingdom: a cost of illness study

Research

Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood

Position statement

Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta

Review

Childhood hypophosphatasia: to treat or not to treat

Research

Dentinogenesis imperfecta type II in Swedish children and adolescents